415 related articles for article (PubMed ID: 24799487)
1. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.
Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Gonzalez-Angulo AM; Kirshner JJ; Krop I; Levinson J; Modi S; Patt DA; Perez EA; Perlmutter J; Winer EP; Lin NU
J Clin Oncol; 2014 Jul; 32(19):2100-8. PubMed ID: 24799487
[TBL] [Abstract][Full Text] [Related]
2. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Kirshner JJ; Krop IE; Levinson J; Modi S; Patt DA; Perlmutter J; Winer EP; Lin NU
J Clin Oncol; 2018 Sep; 36(27):2804-2807. PubMed ID: 29939840
[TBL] [Abstract][Full Text] [Related]
3. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
Ramakrishna N; Anders CK; Lin NU; Morikawa A; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Franzoi MAB; Kirshner JJ; Krop IE; Patt DA; Perlmutter J; Giordano SH
J Clin Oncol; 2022 Aug; 40(23):2636-2655. PubMed ID: 35640075
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
5. Brain metastases in breast cancer: analysis of the role of HER2 status and treatment in the outcome of 94 patients.
Fokas E; Henzel M; Hamm K; Grund S; Engenhart-Cabillic R
Tumori; 2012 Nov; 98(6):768-74. PubMed ID: 23389365
[TBL] [Abstract][Full Text] [Related]
6. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
Kuba S; Ishida M; Nakamura Y; Yamanouchi K; Minami S; Taguchi K; Eguchi S; Ohno S
Jpn J Clin Oncol; 2014 Nov; 44(11):1025-31. PubMed ID: 25156682
[TBL] [Abstract][Full Text] [Related]
7. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
8. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases.
Mehta MP; Tsao MN; Whelan TJ; Morris DE; Hayman JA; Flickinger JC; Mills M; Rogers CL; Souhami L
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):37-46. PubMed ID: 16111570
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Partridge AH; Rumble RB; Carey LA; Come SE; Davidson NE; Di Leo A; Gralow J; Hortobagyi GN; Moy B; Yee D; Brundage SB; Danso MA; Wilcox M; Smith IE
J Clin Oncol; 2014 Oct; 32(29):3307-29. PubMed ID: 25185096
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
11. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.
Vogelbaum MA; Brown PD; Messersmith H; Brastianos PK; Burri S; Cahill D; Dunn IF; Gaspar LE; Gatson NTN; Gondi V; Jordan JT; Lassman AB; Maues J; Mohile N; Redjal N; Stevens G; Sulman E; van den Bent M; Wallace HJ; Weinberg JS; Zadeh G; Schiff D
J Clin Oncol; 2022 Feb; 40(5):492-516. PubMed ID: 34932393
[TBL] [Abstract][Full Text] [Related]
12. Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline.
Schiff D; Messersmith H; Brastianos PK; Brown PD; Burri S; Dunn IF; Gaspar LE; Gondi V; Jordan JT; Maues J; Mohile N; Redjal N; Stevens GHJ; Sulman EP; van den Bent M; Wallace HJ; Zadeh G; Vogelbaum MA
J Clin Oncol; 2022 Jul; 40(20):2271-2276. PubMed ID: 35561283
[TBL] [Abstract][Full Text] [Related]
13. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Harris LN; Ismaila N; McShane LM; Andre F; Collyar DE; Gonzalez-Angulo AM; Hammond EH; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Bast RC; Hayes DF;
J Clin Oncol; 2016 Apr; 34(10):1134-50. PubMed ID: 26858339
[TBL] [Abstract][Full Text] [Related]
14. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update Summary.
Ramakrishna N; Temin S; Lin NU
J Oncol Pract; 2018 Aug; 14(8):505-507. PubMed ID: 29989840
[No Abstract] [Full Text] [Related]
15. Current Treatment Options for Breast Cancer Brain Metastases.
Raghunath A; Desai K; Ahluwalia MS
Curr Treat Options Oncol; 2019 Feb; 20(3):19. PubMed ID: 30771009
[TBL] [Abstract][Full Text] [Related]
16. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
Denduluri N; Somerfield MR; Eisen A; Holloway JN; Hurria A; King TA; Lyman GH; Partridge AH; Telli ML; Trudeau ME; Wolff AC
J Clin Oncol; 2016 Jul; 34(20):2416-27. PubMed ID: 27091714
[TBL] [Abstract][Full Text] [Related]
17. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
18. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
19. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
Giordano SH; Franzoi MAB; Temin S; Anders CK; Chandarlapaty S; Crews JR; Kirshner JJ; Krop IE; Lin NU; Morikawa A; Patt DA; Perlmutter J; Ramakrishna N; Davidson NE
J Clin Oncol; 2022 Aug; 40(23):2612-2635. PubMed ID: 35640077
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
